Develops lipid-based therapies for infectious diseases and oncology, focusing on novel antimicrobial and anti-infective drugs.
Matinas BioPharma Holdings, Inc., based in Bedminster, New Jersey, is a clinical-stage biopharmaceutical company dedicated to advancing a diverse portfolio of product candidates. Founded in 2013, Matinas focuses on leveraging its innovative lipid nanocrystal (LNC) platform technology for the delivery of various therapeutic agents. This platform utilizes lipid nano-crystals to enhance the delivery efficacy of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.
At the forefront of its pipeline is LYPDISO, the company's lead product candidate. LYPDISO is a prescription-only omega-3 free fatty acid-based composition designed to address cardiovascular and metabolic conditions. Matinas is also developing MAT2203, an oral formulation of amphotericin B currently in Phase II clinical trials. This formulation aims to prevent invasive fungal infections in patients undergoing immunosuppressive therapy. Additionally, the company has advanced MAT2501, an orally administered version of the broad-spectrum antibiotic amikacin. MAT2501 has completed Phase I trials and targets various multidrug-resistant bacteria, including non-tuberculous mycobacterium and gram-negative infections.
Collaborative partnerships play a crucial role in Matinas BioPharma's strategy for innovation. The company collaborates with the National Institute of Allergy and Infectious Diseases to explore the potential of Gilead's antiviral remdesivir. Furthermore, a feasibility collaboration with Genentech, Inc. focuses on developing oral formulations for enhanced therapeutic delivery. With a commitment to advancing novel therapies that meet significant medical needs, Matinas BioPharma continues to drive forward in the biopharmaceutical industry, aiming to improve patient outcomes globally.